News of Note—Dynavax, Emergent BioSolutions and more

In this week's News of Note, Dynavax steadily grew sales of its novel hepatitis B vaccine, Heplisav-B. (Pixabay)

Here is some other vaccine news of note for the week:

> Dynavax’s hepatitis B vaccine Heplisav-B sold $1.3 million in the second quarter, up from $0.2 million in the first quarter. Release

> Emergent BioSolutions posted second-quarter revenue of $220 million, an increase of 118% year over year, thanks to sales of anthrax vaccine BioThrax and smallpox vaccine ACAM2000. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Changchun Changsheng Life Sciences, embroiled in China’s latest vaccine scandal, was found to have forged production data for more than four years. Xinhua article

> The International AIDS Vaccine Initiative reached a nonexclusive license agreement with the Public Health Agency of Canada to obtain vesicular stomatitis virus vector technology for a Lassa fever vaccine currently under funding from the Coalition for Epidemic Preparedness Innovations. Release